Royal DSM to spin off pharmaceutical business in US$2.6bn deal

Published: 19-Nov-2013
Manufacturing Drug Delivery Finance Pharmaceutical Dosage Forms

Private equity firm JLL Partners will form a new company by combining DSM Pharmaceutical Products with Patheon


Royal DSM is to spin off its pharmaceuticals business in a deal that will create a US$2.6bn drugmaking business.

The Dutch firm will sell the business to private equity firm JLL Partners, which will form the new company by combining DSM Pharmaceutical Products with Patheon, the drug manufacturer in which it is majority shareholder.

Subject to customary conditions, the deal is expected to close in the first half of next year.

The name of the new company is yet to be announced, but DSM says it will be a leading global contract development and manufacturing organisation (CDMO) with anticipated sales of around $2bn. It will be 51% owned by JLL and 49% by DSM.

Provisionally called NewCo, the company will focus on drug products and APIs with a range of technologies and will offer end-to-end solutions to Big Pharma and biotech companies, as well as specialist pharma companies, generics and emerging pharma companies.

The combined company will also be a leader in proprietary softgel formulations for over-the-counter, prescription and nutritional consumer products.

It will have a global footprint of 23 locations across North America, Europe, Latin America and Australia and around 8,300 employees.

Once the transaction is completed, NewCo will add scale and new capabilities and technologies to expand its end-to-end service offering.

This is for DSM Pharmaceutical Products the perfect way to accelerate growth and for DSM to maximise value for this business

JLL will contribute $489m in cash to NewCo and DSM will contribute DSM Pharmaceutical Products (DPP) and receive $200m, thereby valuing DPP at $670m.

NewCo has entered into a definitive agreement to acquire Patheon for $9.32 per share, which will value Patheon at approximately $1.95bn.

In the 12 months ending 31 July 2013, Patheon had revenues of $943m. The company employs around 5,900 people.

Jim Mullen, currently CEO of Patheon, will become CEO of NewCo upon completion.

Mullen joined Patheon in 2011 as Chief Executive. Prior to this, he was CEO and President of biotechnology company Biogen Idec.

Feike Sijbesma, CEO and Chairman of the DSM Managing Board, said: 'Fully in line with our strategy, this is for DSM Pharmaceutical Products the perfect way to accelerate growth and for DSM to maximise value for this business.'

Paul Levy, Managing Director of JLL Partners and Chairman of the Board of Patheon added: 'This partnership demonstrates JLL's commitment to building companies that create value, fill unmet needs and drive excellence within their respective industries.'

  • Companies:
  • Patheon
  • dsm-firmenich
See more

You may also like

Ingredients

dsm-firmenich showcases excipient and sustainability solutions at CPHI Milan

Read more
The company will present its range of solutions designed to boost patient compliance, while also exhibiting its pharma-grade CBD ingredient

Trending Articles

  1. Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
  2. IMed Consultancy helps Toby Orthopaedics navigate UK regulations Regulatory consultancy ensures compliance and confidence for Miami-based company
  3. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  4. Vetter strengthens senior management team for growth Three new managing directors to support global sustainable development

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Ingredients

dsm-firmenich showcases excipient and sustainability solutions at CPHI Milan

The company will present its range of solutions designed to boost patient compliance, while also exhibiting its pharma-grade CBD ingredient
Manufacturing

dsm-firmenich initiates patent infringement action

dsm-firmenich asserts that Shengda’s production of a key biotin intermediate at its Anhui site is an unlawful use of patented technology
Ingredients

Humanetics acquires all legal assets of DSM radioprotective API

All patents, trademarks, trade secret manufacturing processes of the API for BIO 300 have been sold to US-based Humanetics
Manufacturing

DSM and Chromatic 3D Materials partner

The global science-based company active in health, nutrition and materials, has entered a partnership with the 3D-printer developer to introduce thermoset materials for 3D-printing of finished manufactured goods
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Inside Patheon’s new flexible pharmaceutical development facilities

In the pharmaceutical sector, flexible facilities are in demand as new niche therapies replace traditional blockbusters. Patheon’s Tony Pidgeon, Process Technology Director, and Louise Hall, PMP, Senior Director, Pharmaceutical Development Services, describe improvements made at the company’s new sterile PDS Suite at its Greenville (NC, USA) site to meet the new trend
Manufacturing

Financial gains for choosing a single-source outsourcing partner

Tufts Center for Drug Development study shows that there are multimillion-dollar benefits of using single-source pharma drug development and manufacturing model
Design & Build

Patheon to invest $45m to support continued growth

Investments by the pharmaceutical solutions provider include facility and equipment expansions in key service areas to meet growing customer demand
Subscribe now